These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7160044)

  • 1. Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.
    Ames MM; Miser JS; Smithson WA; Coccia PF; Hughes CS; Davis DM
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):43-6. PubMed ID: 7160044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic conversion of indicine N-oxide to indicine in rabbits and humans.
    Powis G; Ames MM; Kovach JS
    Cancer Res; 1979 Sep; 39(9):3564-70. PubMed ID: 476682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of the antineoplastic agent indicine-N-oxide in human plasma by differential pulse polarography.
    McComish M; Bodek I; Branfman AR
    J Pharm Sci; 1980 Jun; 69(6):727-9. PubMed ID: 7205594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.
    Whitehead VM; Bernstein ML; Vega R; Vats T; Dyment P; Vietti TJ; Krischer J
    Cancer Chemother Pharmacol; 1990; 26(5):377-9. PubMed ID: 2208580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of indicine N-oxide in mice and monkeys.
    El Dareer SM; Tillery KF; Lloyd HH; Hill DL
    Cancer Treat Rep; 1982 Jan; 66(1):183-6. PubMed ID: 7053256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
    Powis G; Ames MM; Kovach JS
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):559-69. PubMed ID: 451340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions.
    Powis G; DeGraw CL
    Res Commun Chem Pathol Pharmacol; 1980 Oct; 30(1):143-50. PubMed ID: 6254119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of indicine N-oxide in relapsed pediatric solid tumors. A report from the Childrens Cancer Study Group.
    Miser JS; Smithson WA; Krivit W; Hughes C; Davis D; Krailo M; Hammond D
    Invest New Drugs; 1991 Nov; 9(4):339-42. PubMed ID: 1804809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450.
    Powis G; Wincentsen L
    Biochem Pharmacol; 1980 Feb; 29(3):347-51. PubMed ID: 6767485
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of indicine N-oxide and indicine in plasma and urine by electron-capture gas-liquid chromatography.
    Ames MM; Powis G
    J Chromatogr; 1978 Dec; 166(2):519-26. PubMed ID: 748361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct quantitative analysis of indicine-N-oxide in cancer patient samples by gas chromatography using the internal standard heliotrine-N-oxide including a mass spectral comparison of their trimethylsilyl derivatives.
    Evans JV; Daley SK; McClusky GA; Nielsen CJ
    Biomed Mass Spectrom; 1980 Feb; 7(2):65-73. PubMed ID: 7407334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic failure secondary to indicine N-oxide toxicity. A Pediatric Oncology Group Study.
    Cook BA; Sinnhuber JR; Thomas PJ; Olson TA; Silverman TA; Jones R; Whitehead VM; Ruymann FB
    Cancer; 1983 Jul; 52(1):61-3. PubMed ID: 6573942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
    Thompson P; Balis F; Serabe BM; Berg S; Adamson P; Klenke R; Aiken A; Packer R; Murry DJ; Jakacki R; Blaney SM
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):417-23. PubMed ID: 12879279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.
    Kovach JS; Ames MM; Powis G; Moertel CG; Hahn RG; Creagan ET
    Cancer Res; 1979 Nov; 39(11):4540-4. PubMed ID: 498086
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacology of bruceantin by radioimmunoassay.
    Fong KL; Ho DH; Benjamin RS; Brown NS; Bedikian A; Yap BS; Wiseman CL; Kramer W; Bodey GP
    Cancer Chemother Pharmacol; 1982; 9(3):169-72. PubMed ID: 7160053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide.
    Letendre L; Ludwig J; Perrault J; Smithson WA; Kovach JS
    Cancer; 1984 Oct; 54(7):1256-9. PubMed ID: 6590115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indicine-N-oxide: a new antitumor agent.
    Poster DS; Bruno S; Penta J; Macdonald JS
    Cancer Treat Rep; 1981; 65(1-2):53-6. PubMed ID: 6939484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: a mechanism for its cytotoxic activity.
    Appadurai P; Rathinasamy K
    Toxicol Lett; 2014 Feb; 225(1):66-77. PubMed ID: 24300171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.